Adaptive pathways program to continue after EMA's 2-year pilot

LONDON – It's so far, so good for adaptive pathways, with the EMA's final report on its pilot scheme concluding that staggered approval from a small patient subgroup to an increasingly wide patient population can support development in indications where it is hard to generate sufficient data.